Glucagonlike peptide I (7–37) [GLP-I-(7–37)], encoded with glucagon and glucagonlike peptide II and intervening peptide II in the rat and human glucagon gene, is processed from proglucagon in both pancreas and intestine and is a potent stimulator of insulin secretion. Unequivocal insulin release from the isolated perfused rat pancreas is elicited by a 10−11 M concentration of this peptide, and a weak response is found at 10−12 M. We found that GLP-I-(7–37) is ∼100 times more potent than glucagon in the stimulation of insulin secretion. Insulin release in response to GLP-I-(7–37) is highly dependent on the ambient glucose concentration; no response is detectable at a glucose concentration of 2.8 mM, and at 6.6 and 16.7 mM, insulin release is augmented by 4.7 and 22.8 ng/ml, respectively. The pattern of insulin secretion stimulated by GLP-I-(7–37) is biphasic, with an initial spike followed by a plateau of sustained release. The effects on insulin release of GLP-I-(7–36) amide, a GLP-I analogue, and GLP-I-(7–37) at concentrations of 10−11 M were indistinguishable. We also found that GLP-I-(7–37) at 10−9 M does not influence glucagon secretion and that glucagonlike peptide II and the intervening peptide II, two other peptides encoded by the glucagon gene, have no detectable effects on insulin secretion.
Skip Nav Destination
Article navigation
Original Articles|
March 01 1989
Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas
Gordon C Weir;
Gordon C Weir
Joslin Diabetes Center and New England Deaconess Hospital, Harvard and the Laboratory of Molecular Endocrinology, Massachusetts General Hospital and Howard Hughes Medical Institute, Harvard Medical School
Boston, Massachusetts
Search for other works by this author on:
Svetlana Mojsov;
Svetlana Mojsov
Joslin Diabetes Center and New England Deaconess Hospital, Harvard and the Laboratory of Molecular Endocrinology, Massachusetts General Hospital and Howard Hughes Medical Institute, Harvard Medical School
Boston, Massachusetts
Search for other works by this author on:
Grant K Hendrick;
Grant K Hendrick
Joslin Diabetes Center and New England Deaconess Hospital, Harvard and the Laboratory of Molecular Endocrinology, Massachusetts General Hospital and Howard Hughes Medical Institute, Harvard Medical School
Boston, Massachusetts
Search for other works by this author on:
Joel F Habener
Joel F Habener
Joslin Diabetes Center and New England Deaconess Hospital, Harvard and the Laboratory of Molecular Endocrinology, Massachusetts General Hospital and Howard Hughes Medical Institute, Harvard Medical School
Boston, Massachusetts
Search for other works by this author on:
Address correspondence and reprint requests to Gordon C. Weir, MD, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215.
Diabetes 1989;38(3):338–342
Article history
Received:
May 02 1988
Revision Received:
September 07 1988
Accepted:
September 07 1988
PubMed:
2645190
Citation
Gordon C Weir, Svetlana Mojsov, Grant K Hendrick, Joel F Habener; Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas. Diabetes 1 March 1989; 38 (3): 338–342. https://doi.org/10.2337/diab.38.3.338
Download citation file:
255
Views